Literature DB >> 2989620

Prevention of free radical-induced myocardial reperfusion injury with allopurinol.

J R Stewart, S L Crute, V Loughlin, M L Hess, L J Greenfield.   

Abstract

Growing evidence supports the concept that oxygen free radicals are an important cause of myocardial ischemic and reperfusion injury. This study was designed to determine if toxic oxygen metabolites may exacerbate ischemic injury upon reoxygenation. Left ventricular function was studied in a group of seven dogs receiving intermittent, 4 degrees C, hyperosmolar, hyperkalemic (KCI 25 mEq/L) saline cardioplegic solution. This group was compared to a group (n = 7) receiving a hyperkalemic (KCI 25 mEq/L) cardioplegic solution designed to scavenge superoxide anion and hydroxyl radical: superoxide dismutase (3,000 U/ml) and mannitol (325 mOsm/L). A third group of five animals received allopurinol pretreatment (50 mg/kg/day) for 72 hours and hyperkalemic saline cardioplegic solution. After 60 minutes of ischemia (10 degrees to 15 degrees C) and 45 minutes of reperfusion, left ventricular mechanical function was better in the groups receiving free radical scavengers and allopurinol pretreatment than in the group receiving only hyperkalemic saline cardioplegic solution. Free radical scavengers preserved myocardial function in this model of hypothermic global ischemia and reperfusion. Our data support the concept that injury occurs primarily during reperfusion with the generation of oxygen free radicals via the hypoxanthine-xanthine oxidase reaction. Allopurinol has potential clinical application in the prevention of reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989620

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  20 in total

Review 1.  Reactive oxygen metabolites and the human myocardium.

Authors:  C J Burrell; D R Blake
Journal:  Br Heart J       Date:  1989-01

2.  Allopurinol enhanced adenine nucleotide repletion after myocardial ischemia in the isolated rat heart.

Authors:  R D Lasley; S W Ely; R M Berne; R M Mentzer
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  Lipid peroxidation during myocardial reperfusion.

Authors:  C Ceconi; A Cargnoni; E Pasini; E Condorelli; S Currello; R Ferrari
Journal:  Mol Cell Biochem       Date:  1992-04       Impact factor: 3.396

Review 4.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

Review 5.  Biochemical mechanisms for oxygen free radical formation during exercise.

Authors:  B Sjödin; Y Hellsten Westing; F S Apple
Journal:  Sports Med       Date:  1990-10       Impact factor: 11.136

Review 6.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

7.  Allopurinol-enhanced myocardial protection does not involve xanthine oxidase inhibition or purine salvage.

Authors:  D J Chambers; A Takahashi; S M Humphrey; D M Harvey; D J Hearse
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

8.  Efficacy of 15-(123I)-p-iodophenyl pentadecanoic acid (IPPA) in assessing myocardial metabolism in a model of reversible global ischemia.

Authors:  M P Hudon; D M Lyster; E W Jamieson; K A Qayumi; M C Kiess; L J Rosado; A P Autor; C Sartori; H Dougan; J van den Broek
Journal:  Eur J Nucl Med       Date:  1988

9.  The effect of supplementing hypothermic crystalloid cardioplegia with catalase plus allopurinol in the isolated rabbit heart.

Authors:  K Nishida
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 10.  Could treatment with scavengers of oxygen free radicals minimize complications in cardiac surgery?

Authors:  J Vaage; G Valen
Journal:  Klin Wochenschr       Date:  1991-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.